Zynyz: An Intravenous Route Drug For The Treatment of Merkel Cell Carcinoma

Introduction

Zynyz, also known as Retifanlimab-Dlwr, is an intravenous route drug used to treat Merkel Cell Carcinoma (MCC), a type of skin cancer which returns or spreads. It is available in the brand name, Zynyz, in the United States, and is administered only under the direct supervision of the doctor.

Dosage Forms

Zynyz is available in the form of a solution for injection. It is important to read and follow all product instructions before usage.

Before Using Zynyz

It is important to inform the doctor of any medical conditions, allergies, or any medications that are being taken before starting the treatment with Zynyz. Women who are pregnant or planning to become pregnant should inform the doctor, as it is still unclear whether the drug can affect the fetus.

Side Effects

The side effects of Zynyz may include vision problems, dizziness, severe or sudden headache, or severe headache lasting for more than 2 days. Other cases may include mood or behavior changes, nausea and vomiting, liver damage, heartburn, difficulty breathing, rash, and itching. It is important to inform the doctor if any of these side effects occur.

Final Thoughts

Zynz, also known as Retifanlimab-Dlwr, is an intravenous route drug used to treat Merkel Cell Carcinoma (MCC). It is only administered under the direct supervision of the doctor. Patients must inform the doctor of any medical conditions, allergies, or medications before beginning Zynyz, as well as should inform the doctor if any side effects occur. Despite the possible side effects, it is an effective drug for the treatment of MCC.